Literature DB >> 27076357

Dissecting intensive treatment as risk factor for inhibitor development in haemophilia.

C L Eckhardt1, A S van Velzen1, C J Fijnvandraat1, J G van der Bom2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27076357     DOI： 10.1111/hae.12944

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  2 in total

1.  Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A.

Authors:  Yohann Repessé; Catherine Costa; Roberta Palla; Elika Farrokhi Moshai; Annie Borel-Derlon; Roseline D'Oiron; Chantal Rothschild; Amal El-Beshlawy; Mohsen Elalfy; Vijay Ramanan; Peyman Eshghi; Johannes Oldenburg; Anna Pavlova; Frits R Rosendaal; Flora Peyvandi; Srinivas V Kaveri; Sébastien Lacroix-Desmazes
Journal:  Haematologica       Date:  2019-01-31       Impact factor: 9.941

2.  Thrombocytopenia and bleeding in myelosuppressed transfusion-dependent patients: a simulation study exploring underlying mechanisms.

Authors:  Rutger A Middelburg; Jean-Louis H Kerkhoffs; Johanna G van der Bom
Journal:  Clin Epidemiol       Date:  2018-04-11       Impact factor: 4.790
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.